Steve Schonfeld’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-43,599
Closed -$2.1M 2807
2026
Q1
$2.1M Sell
43,599
-20,396
-32% -$904K 0.01% 801
2025
Q4
$2.64M Sell
63,995
-19,886
-24% -$798K 0.01% 777
2025
Q3
$3.26M Buy
83,881
+15,130
+22% +$492K 0.02% 797
2025
Q2
$1.9M Buy
68,751
+18,904
+38% +$481K 0.01% 1011
2025
Q1
$1.11M Buy
49,847
+21,447
+76% +$441K 0.01% 1241
2024
Q4
$562K Sell
28,400
-60,900
-68% -$1.39M ﹤0.01% 1343
2024
Q3
$2.23M Buy
89,300
+909
+1% +$22.1K 0.01% 834
2024
Q2
$1.65M Sell
88,391
-128,517
-59% -$2.41M 0.01% 991
2024
Q1
$4.28M Sell
216,908
-9,543
-4% -$186K 0.03% 705
2023
Q4
$3.97M Buy
226,451
+17,951
+9% +$295K 0.03% 577
2023
Q3
$3.62M Buy
208,500
+134,070
+180% +$2.26M 0.03% 642
2023
Q2
$1.05M Buy
74,430
+9,432
+15% +$126K 0.01% 951
2023
Q1
$699K Buy
64,998
+14,998
+30% +$198K 0.01% 1065
2022
Q4
$749K Buy
+50,000
New +$728K 0.01% 1309
2020
Q3
Sell
-15,900
Closed -$405K 1514
2020
Q2
$405K Buy
+15,900
New +$332K 0.01% 882
2020
Q1
Sell
-38,900
Closed -$430K 1338
2019
Q4
$430K Buy
+38,900
New +$338K 0.01% 813

Other funds holding KNSA

Steve Schonfeld's KNSA Position: Q2 2026 in Review

Steve Schonfeld sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 43,599 shares — an estimated $2.1M sold.

Steve Schonfeld first reported a position in KNSA in Q4 2019 and held it in 16 quarters. The position peaked at $4.28M in Q1 2024. 265 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Steve Schonfeld reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 43,599 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.1M.
  • Steve Schonfeld first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 16 quarters.
  • Steve Schonfeld's Kiniksa Pharmaceuticals position peaked at $4.28M in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.